Hasbani Follows Up The Death Of Farah Kassab And Issues Two Decisions And Two Letters To The General

Hasbani Follows up the Death of Farah Kassab and Issues Two Decisions and Two Letters to the General Prosecution and the Order of Physicians

The Information Office of Deputy Prime Minister Health Minister Ghassan Hasbani issued the following statement:

In the context of following up the death of Farah Kassab after she underwent a cosmetic surgery in a specialized hospital in cosmetic surgeries,

Health Minister Ghassan Hasbani took the following actions:

The issuance of a decision on the prevention of surgical operations that require a general anesthetic in day hospitals or other cosmetic surgery clinics.
The issuance of a decision on the prevention of surgical operations that require a general anesthetic in Dr. Nader Saab hospital specialized in cosmetic surgery.
The issuance of a letter to the Public Prosecutor to investigate into the death of Farah Kassab.
The issuance of a letter to the Lebanese Order of Physicians in Beirut to conduct necessary investigations into the death of Farah Kassab, and give the Order a period of two weeks to clarify some technical medical points and answer questions asked by Health Minister concerning the death of the said woman.

These steps came to complete the immediate oral decision of Health Minister Ghassan Hasbani to cease operations in the said clinic after the woman's death, and the written decision issued Friday 2 June 2017 which stipulates the following:

Surgeries that may cause complications that require intensive care like liposuction and other surgeries shall not performed in places other than specialized hospitals which include an intensive care division that holds a license form Health Ministry in accordance with due process.
The doctor should explain to the patient the risks of the surgery, including the plastic surgery, and ask the patient to sign the Patient Right Form and the informed consent.

All

ATC	Name	B/G	Ingredients	Dosage	Form	Price
B02BX06	HEMLIBRA	BioTech	Emicizumab - 60mg/0.4ml	60mg/0.4ml	Injectable solution	441,042,377 L.L
B02BX06	HEMLIBRA	BioTech	Emicizumab - 30mg/ml	30mg/ml	Injectable solution	224,585,721 L.L
B02BX06	HEMLIBRA	BioTech	Emicizumab - 150mg/ml	150mg/ml	Injectable solution	895,547,224 L.L
B02BX06	HEMLIBRA	BioTech	Emicizumab - 105mg/0.7ml	105mg/0.7ml	Injectable solution	722,177,054 L.L
B02BX06	HEMLIBRA	BioTech	Emicizumab - 30mg/ml	30mg/ml	Injectable solution	L.L
B02BX06	HEMLIBRA	BioTech	Emicizumab - 60mg/0.4ml	60mg/0.4ml	Injectable solution	L.L
B03XA01	HEMAX	BioTech	Erythropoietin recombinant human (Epoetin alfa) - 4,000IU	4,000IU	Injectable freeze dried substance+diluent	940,690 L.L
B03XA01	HEMAX	BioTech	Erythropoietin recombinant human (Epoetin alfa) - 4,000IU	4,000IU	Injectable freeze dried substance+diluent	33,852,747 L.L
B03XA01	HEMAX	BioTech	Erythropoietin recombinant human (Epoetin alfa) - 10,000IU	10,000IU	Injectable freeze dried substance+diluent	2,490,140 L.L
B03XA01	HEMAX	BioTech	Erythropoietin recombinant human (Epoetin alfa) - 20,000IU	20,000IU	Injectable freeze dried powder + diluent	5,438,531 L.L
B03XA01	HEMAX	BioTech	Erythropoietin recombinant human (Epoetin alfa) - 40,000IU	40,000IU	Injectable freeze dried powder + diluent	6,316,060 L.L
B03XA01	HEMAX	BioTech	Erythropoietin recombinant human (Epoetin alfa) - 10,000IU	10,000IU	Injectable freeze dried substance+diluent	L.L
B03XA01	HEMAX	BioTech	Erythropoietin recombinant human (Epoetin alfa) - 40,000IU	40,000IU	Injectable freeze dried powder + diluent	L.L
B05AA01	HUMAN ALBUMIN "OCTAPHARMA" 20%	BioHuman	Albumin human - 20%	20%	Injectable solution	4,863,366 L.L
B05AA01	HUMAN ALBUMIN 20% SOLUTION	BioHuman	Albumin human - 20%	20%	Injectable solution	4,343,343 L.L
B05AA01	HUMAN ALBUMIN BEHRING 20%, LOW SALT	BioHuman	Albumin human - 20%	20%	Injectable solution	4,343,343 L.L
B05BB02	HI-SODIUM WITHOUT POTASSIUM INJECTION	G	Sodium dihydrogenophosphate - 0.137g/100ml, Sodium lactate (anhydre) - 0.223g/100ml, Sodium chloride - 0.175g/100ml, Dextrose monohydrate - 5g/100ml		Injectable solution	166,708 L.L
B05BB02	HI-SODIUM INJECTION	G	Sodium lactate - 0.223g%, Sodium dihydrogenophosphate - 0.137g%, Potassium chloride - 0.149g%, Sodium chloride - 0.175g%, Dextrose, H2O - 5.0g%		Injectable solution	176,024 L.L
B05BB02	HI-SODIUM INJECTION WITH POTASSIUM	G	Potassium chloride - 0.149g/100ml, Sodium dihydrogenophosphate - 0.137g/100ml, Sodium lactate (anhydre) - 0.223g/100ml, Sodium chloride - 0.175g/100ml, Dextrose monohydrate - 5g/100ml		Injectable solution	165,727 L.L
B05XA03	HYPOTONIC SALINE	G	Sodium chloride - 0.45%	0.45%	Injectable solution	149,393 L.L
B05XA03	HYPOTONIC SALINE	G	Sodium chloride - 0.45%	0.45%	Injectable solution	163,184 L.L
C03BA04	HYGROTON	B	Chlortalidone - 50mg	50mg	Tablet	422,351 L.L
C03DA04	HEPERONA 25	G	Eplerenone - 25mg	25mg	Tablet, coated	2,116,552 L.L
C03DA04	HEPERONA 50	G	Eplerenone - 50mg	50mg	Tablet, coated	2,150,148 L.L
C05AX	HEMOCARE	G	Bismuth subgallate - 100mg, Zinc oxide - 100mg, Lidocaine - 60mg		Suppository	588,731 L.L
C08CA01	HYPODIPINE 5	G	Amlodipine (besylate) - 5mg	5mg	Capsule	362,837 L.L
C09DA01	HYZAAR	B	Losartan potassium - 50mg, Hydrochlorothiazide - 12.5mg		Tablet	1,523,022 L.L
C09DA01	HYZAAR	B	Losartan potassium - 100mg, Hydrochlorothiazide - 12.5mg		Tablet	1,740,596 L.L
D03AX	HEALIN B	G	β-sitosterol - 0.25%	0.25%	Ointment	849,820 L.L
D04AA32	HISTERGAN	G	Diphenhydramine HCl - 2%	2%	Cream	546,944 L.L